Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

13.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.2K
Amyloid Fibrils03:03

Amyloid Fibrils

7.0K
7.0K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

2
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
2

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidimensional Safety Assessment of a Low-Intensity Scanning Ultrasound (SUS) Protocol in Sheep.

Ultrasound in medicine & biology·2026
Same author

Tau T205 phosphorylation modulates engram cell recruitment and remote memory in mice.

Nature communications·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

A pilot safety and tolerability study of scanning ultrasound as a neuromodulation therapy in Alzheimer's disease.

Brain communications·2025
Same author

Think sepsis, write sepsis, code sepsis - patient characteristics associated with sepsis (under-)coding in administrative health data.

Infection·2025
Same author

Feasibility of ultrasound-mediated blood-brain barrier opening in sheep using sonolucent cranial implants.

Scientific reports·2025

Related Experiment Video

Updated: Apr 19, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

20.1K

Tau aggregation and its interplay with amyloid-β.

Rebecca M Nisbet1, Juan-Carlos Polanco, Lars M Ittner

  • 1Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Australia, r.nisbet@uq.edu.au.

Acta Neuropathologica
|December 11, 2014
PubMed
Summary

Alzheimer's disease (AD) involves amyloid-beta (Aβ) and tau pathologies. Research suggests Aβ may drive tau toxicity, with potential for novel immunotherapies targeting both molecules to improve AD treatment.

More Related Videos

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain
09:35

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Published on: October 24, 2017

13.2K
Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
12:58

Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy

Published on: September 12, 2019

10.4K

Related Experiment Videos

Last Updated: Apr 19, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

20.1K
Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain
09:35

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Published on: October 24, 2017

13.2K
Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
12:58

Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy

Published on: September 12, 2019

10.4K

Area of Science:

  • Neuroscience
  • Pathology
  • Immunology

Background:

  • Alzheimer's disease (AD) is characterized by neurofibrillary tangles (tau protein aggregates) and amyloid plaques (amyloid-beta, Aβ).
  • While plaques and tangles are end-stage lesions, soluble oligomers of Aβ and tau are increasingly recognized as key neurotoxic agents.
  • The precise order of Aβ and tau pathology in AD pathogenesis remains a critical question.

Purpose of the Study:

  • To explore the interplay between amyloid-beta and tau pathologies in Alzheimer's disease.
  • To investigate the role of amyloid-beta in mediating tau toxicity.
  • To evaluate current and novel therapeutic strategies, including immunotherapy, for Alzheimer's disease.

Main Methods:

  • Review of existing literature and experimental models investigating Aβ and tau interactions.
  • Analysis of the role of specific kinases, such as Src kinase Fyn, in Aβ-mediated tau toxicity.
  • Discussion of therapeutic approaches, focusing on immunotherapy and single-chain antibodies.

Main Results:

  • Evidence suggests amyloid-beta may exert toxicity, at least in part, through tau, with Fyn kinase involvement.
  • Both separate and synergistic toxic mechanisms of Aβ and tau have been observed.
  • Integrating these complex interactions into a coherent model of AD pathogenesis is challenging.

Conclusions:

  • Understanding the crosstalk between Aβ and tau is crucial for developing effective AD therapies.
  • Current immunotherapies may have limitations; novel strategies, such as single-chain antibodies, show promise.
  • Further research is needed to determine if targeting one molecule can neutralize the toxicity of the other.